Diminished lipocalin-type prostaglandin D2 synthase expression in human lung tumors

Louis Ragolia, Thomas Palaia, Christopher E. Hall, Jonathan Klein, Arzu Büyük

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Previously, we demonstrated that lipocalin-type prostaglandin D2 synthase (L-PGDS) induces apoptosis and prevents cell cycle progression in several cell types. In this study we determined the expression of L-PGDS in a variety of human lung tumor types. While L-PGDS expression was evident in the surrounding margins, we observed significantly decreased protein and gene expression in the tumor tissue. Using RT-PCR we demonstrated that L-PGDS gene expression decreased proportionately with tumor progression. In addition, we demonstrated that exogenously added L-PGDS could suppress the hyperproliferation and PDGF-stimulated migration of A549 cells, a cultured carcinomic human alveolar basal epithelial cell line. We conclude that L-PGDS may play a key role in modulating lung cancer growth and may offer a novel diagnostic and therapeutic approach for treatment.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalLung Cancer
Volume70
Issue number1
DOIs
StatePublished - Oct 2010
Externally publishedYes

Keywords

  • A549
  • Adenocarcinoma
  • Cancer
  • Lipocalin
  • Lung
  • Prostaglandin D

Fingerprint

Dive into the research topics of 'Diminished lipocalin-type prostaglandin D2 synthase expression in human lung tumors'. Together they form a unique fingerprint.

Cite this